Amarantus Bioscience Holdings Inc (AMBS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
655 MONTGOMERY STREET SAN FRANCISCO, CA 94111 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2016 MRQ | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 176,000 | 214,000 | 1,032,634 | 157,174 | |||
| Cash and cash equivalents | 176,000 | 214,000 | 1,032,634 | 157,174 | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | 519,620 | ||
| Other undisclosed current assets | 652,000 | 198,000 | 215,186 | ||||
| Total current assets: | 828,000 | 412,000 | 1,247,820 | 676,794 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 115,000 | 145,000 | |||||
| Intangible assets, net (including goodwill), including: | 2,861,000 | 1,497,000 | 611,094 | ✕ | |||
| Goodwill | 7,967,000 | ||||||
| Intangible assets, net (excluding goodwill) | 2,861,000 | 1,497,000 | 611,094 | ||||
| Other undisclosed intangible assets, net (including goodwill) | (7,967,000) | ✕ | ✕ | ||||
| Other undisclosed noncurrent assets | 7,967,000 | 204,000 | 533,143 | ||||
| Total noncurrent assets: | 10,943,000 | 1,846,000 | 611,094 | 533,143 | |||
| TOTAL ASSETS: | 11,771,000 | 2,258,000 | 1,858,914 | 1,209,937 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 7,723,000 | 3,527,000 | 1,263,594 | 2,596,848 | |||
| Interest and dividends payable | 195,000 | 25,000 | |||||
| Accounts payable | 3,353,000 | 971,199 | 2,596,848 | ||||
| Accrued liabilities | 149,000 | 292,395 | |||||
| Other undisclosed accounts payable and accrued liabilities | 7,528,000 | ||||||
| Debt | 1,000,000 | 931,942 | 740,000 | ||||
| Derivative instruments and hedges, liabilities | 5,098,000 | 5,859,170 | 26,893 | ||||
| Due to related parties | 257,000 | 252,000 | 247,967 | 222,083 | |||
| Other undisclosed current liabilities | 2,114,000 | 2,550,000 | 236,517 | 1,151,929 | |||
| Total current liabilities: | 16,192,000 | 6,329,000 | 8,539,190 | 4,737,753 | |||
| Noncurrent Liabilities | |||||||
| Other undisclosed noncurrent liabilities | 1,113,000 | ||||||
| Total noncurrent liabilities: | 1,113,000 | ||||||
| Total liabilities: | 17,305,000 | 6,329,000 | 8,539,190 | 4,737,753 | |||
| Temporary equity, carrying amount | 3,154,000 | ||||||
| Equity | |||||||
| Equity, attributable to parent, including: | (8,688,000) | (4,071,000) | (7,519,170) | (3,527,816) | |||
| Common stock | 21,000 | 842,000 | 574,172 | 342,517 | |||
| Additional paid in capital | 74,767,000 | 45,050,000 | 18,938,039 | 7,991,465 | |||
| Accumulated deficit | (92,241,000) | (55,183,000) | |||||
| Other undisclosed equity, attributable to parent | 8,765,000 | 5,220,000 | (27,031,381) | (11,861,798) | |||
| Other undisclosed equity | 838,894 | ||||||
| Total equity: | (8,688,000) | (4,071,000) | (6,680,276) | (3,527,816) | |||
| TOTAL LIABILITIES AND EQUITY: | 11,771,000 | 2,258,000 | 1,858,914 | 1,209,937 | |||
Income Statement (P&L) (USD)
| 3/31/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Operating expenses | (24,821,000) | (21,354,000) | (5,711,134) | (4,096,473) | ||
| Other operating expense, net (Other Expenses) | (9,000) | |||||
| Other undisclosed operating income (loss) | 9,000 | (1,039,145) | ||||
| Operating loss: | (24,821,000) | (21,354,000) | (5,711,134) | (5,135,618) | ||
| Nonoperating income (expense) | (393,000) | (5,923,000) | (9,420,547) | 485,006 | ||
| Investment income, nonoperating | 4,105,000 | 317,000 | 271,191 | 485,006 | ||
| Interest and debt expense | (1,296,000) | (2,063,000) | (9,339,642) | |||
| Loss from continuing operations before equity method investments, income taxes: | (26,510,000) | (29,340,000) | (24,471,323) | (4,650,612) | ||
| Other undisclosed income from continuing operations before income taxes | 1,297,000 | 2,062,000 | 9,340,642 | |||
| Loss from continuing operations: | (25,213,000) | (27,278,000) | (15,130,681) | (4,650,612) | ||
| Loss before gain (loss) on sale of properties: | (25,213,000) | (27,278,000) | (15,130,681) | (4,650,612) | ||
| Other undisclosed net income | 560,270 | |||||
| Net loss: | (25,213,000) | (27,278,000) | (15,130,681) | (4,090,342) | ||
| Other undisclosed net income (loss) attributable to parent | (1,000) | 1,000 | (1,000) | (1,045,276) | ||
| Net loss attributable to parent: | (25,214,000) | (27,277,000) | (15,131,681) | (5,135,618) | ||
| Preferred stock dividends and other adjustments | (3,595,000) | (875,000) | (38,402) | |||
| Other undisclosed net loss available to common stockholders, basic | (8,249,000) | |||||
| Net loss available to common stockholders, basic: | (37,058,000) | (28,152,000) | (15,170,083) | (5,135,618) | ||
| Convertible preferred dividends | (8,249,000) | |||||
| Net loss available to common stockholders, diluted: | (45,307,000) | (28,152,000) | (15,170,083) | (5,135,618) | ||
Comprehensive Income (USD)
| 3/31/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net loss: | (25,213,000) | (27,278,000) | (15,130,681) | (4,090,342) | ||
| Comprehensive loss, net of tax, attributable to parent: | (25,213,000) | (27,278,000) | (15,130,681) | (4,090,342) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.